로딩 중...
52주 최고가 대비 97.9% 위치
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $4.58B | $4.50B | $4.37B | $4.34B |
| 영업이익 | - | $354.0M | $-222.0M | $600.0M | $817.0M |
| 당기순이익 | - | $-4.40B | $-1.16B | $-1.22B | $850.0M |
| 잉여현금흐름 (FCF) | - | $106.0M | $283.0M | $709.0M | $931.0M |
| 수익성 비율 | |||||
| 영업이익률 | - | 7.7% | -4.9% | 13.7% | 18.8% |
| 순이익률 | - | -96.1% | -25.8% | -28.0% | 19.6% |
| ROE (자기자본이익률) | - | -66.7% | -20.2% | -51.5% | 31.2% |
| ROA (자산이익률) | - | -35.9% | -11.5% | -19.4% | 12.8% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | -1.7% | -2.9% | -0.7% |
| EPS 성장률 (YoY) | - | - | 73.8% | -4.8% | 170.9% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | 26.6x |
| PBR (주가순자산배수) | - | 4.8x | 3.7x | 8.5x | 8.0x |
| PSR (주가매출배수) | - | 6.9x | 4.7x | 4.6x | 5.0x |
| FCF Yield | - | 0.3% | 1.3% | 3.5% | 4.2% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.54 | 0.39 | 1.10 | 0.94 |
| 유동비율 | - | 1.28 | 1.66 | 1.78 | 2.08 |
MOLINA HEALTHCARE INC
$179.86
$9.4B